Latest News

Open Orphan says hVIVO builds commercial momentum with £2.5mln influenza challenge study contract


Open Orphan PLC (LON:ORPH) said its hVIVO arm has won a £2.5mln contract to carry out an influenza human challenge study for an unnamed US biotechnology company.

The latest deal builds on significant new business wins in the areas of respiratory syncytial virus and coronavirus (COVID-19).

The challenge study will take place at the company’s 24-bedroom quarantine clinic in east London in the second half of next year with completion due by the end of 2021.

Open Orphan’s Venn Life Sciences Paris team will carry out the biometrics.

“Recent events have highlighted the importance of treatments for viral infections such as influenza and we are seeing an increased level of interest amongst both pharma and biotech in developing innovative new vaccines, antivirals, and therapeutics,” Open Orphan chairman Cathal Friel said in a statement.

FTSE 100 seen positive as equity markets rise whilst US vote count continues

Previous article

DFS says new England lockdown not expected to impact profits

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News